Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $0.53 which represents a decrease of $-0.02 or -3.64% from the prior close of $0.55. The stock opened at $0.54 and touched a low ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report) ...

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...

This page features the latest news about the Mersana Therapeutics stock. MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a ...

Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a new 52-week low, trading at $0.56, as the biopharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) exploded on Wednesday and had a big follow-through on Thursday, with a pop of 1.50, or 8.25%, to 19.69, after reaching a multi-week and ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday ...